Medovex Corp Financials

Based on the analysis of Medovex Corp's profitability, liquidity, and operating efficiency, Medovex Corp is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.
With this module, you can analyze Medovex financials for your investing period. You should be able to track the changes in Medovex Corp individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past Medovex Corp Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Medovex Corp's financial statements are interrelated, with each one affecting the others. For example, an increase in Medovex Corp's assets may result in an increase in income on the income statement.
The data published in Medovex Corp's official financial statements typically reflect Medovex Corp's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Medovex Corp's quantitative information. For example, before you start analyzing numbers published by Medovex accountants, it's essential to understand Medovex Corp's liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Please note, the imprecision that can be found in Medovex Corp's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Medovex Corp. Check Medovex Corp's Beneish M Score to see the likelihood of Medovex Corp's management manipulating its earnings.

Medovex Corp Stock Summary

Medovex Corp competes with Ascletis Pharma, Genelux Common, Dyadic International, Cingulate, and Monopar Therapeutics. H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. H CYTE operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 8 people.
InstrumentUSA OTC Stock View All
ExchangeOTCQB Exchange
ISINUS4041241096
Business Address2202 North West
SectorHealthcare
IndustryBiotechnology
BenchmarkDow Jones Industrial
Websitewww.hcyte.com
Phone888 664 2983
CurrencyUSD - US Dollar

Medovex Corp Key Financial Ratios

Medovex Corp's financial ratios allow both analysts and investors to convert raw data from Medovex Corp's financial statements into concise, actionable information that can be used to evaluate the performance of Medovex Corp over time and compare it to other companies across industries.

Medovex Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Medovex Corp's current stock value. Our valuation model uses many indicators to compare Medovex Corp value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Medovex Corp competition to find correlations between indicators driving Medovex Corp's intrinsic value. More Info.
Medovex Corp is rated below average in return on equity category among its peers. It is rated # 2 in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Medovex Corp's earnings, one of the primary drivers of an investment's value.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Consideration for investing in Medovex OTC Stock

If you are still planning to invest in Medovex Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Medovex Corp's history and understand the potential risks before investing.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance